ADCendo ApS raises 51m in Series A financing
Danish ADCendo ApS will use the funds from a Series A investment to advance Antibody-Drug Conjugates (ADCs) entering cancer cells through endocytic receptors.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1125 entries already.
Entries by Thomas Gabrielczyk
DNA Script bags DARPA funding
/in News/by Thomas GabrielczykDNA Script will receive a $5m DARPA grant as part of the agency’s Nucleic Acids On-Demand World-Wide Program to prevent the next viral pandemic.
First malaria vaccine meets WHO efficacy criteria
/in News/by Thomas GabrielczykResearchers at Novavax and from the University of Oxford reported an efficacy of 77% of their malaria vaccine, R21/Matrix-M from a Phase II trials in Burkina Faso.
European COVID-19 antibody enters Phase III testing
/in News/by Thomas GabrielczykGSK’s and Vir Therapeutics COVID-19 antibody treatment VIR-7831 has entered Phase III testing within the UKs COVID-19 drug testing platform, AGILE
J&J starts European COVID-19 vaccine roll-out
/in News/by Thomas GabrielczykAfter a positive re-evaluation of J&Js COVID-19 vaccine by the European Medicines Agency (EMA), J&J has re-started to ship 55 million doses to the EU.
Endeavour Medtech Growth II LP closes at $375m
/in News/by Thomas GabrielczykEndeavour Vision has announced the closing of its Heathtech fund Endeavour Medtech Growth II (EMG II) LP at US$375 million in capital commitments.
Record year for Swiss biotech industry
/in News/by Thomas GabrielczykThe Swiss biotech industry experienced a record investment in the pandemic year 2020, according to the new Swiss Biotech Report.
EU orders 100 million additional doses from Biontech
/in News/by Thomas GabrielczykThe European Union has exercised its option to order 100 million additional doses of BNT162b2 bringing its orders to 600 million doses at 14.70 per shot.
COVID-19: Study finds neutralising antibodies to disappear rapidly
/in News/by Thomas GabrielczykA new study on the persistence of neutralising antibodies to SARS-CoV-2 in the blood suggests that humoral immunity will drop 5 months after vaccination.
BioVersys gets 20m EIB loan to develop novel antibiotics
/in News/by Thomas GabrielczykSwiss BioVersys has received 20mfrom the European Investment Bank to push the development of new drugs against life-threatening nosocomial infections.